Name | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase II contract was awarded to Orphagen Pharmaceuticals in July, 2021 for $1,306,362.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44CA265639-01 | Phase II | 1,306,362 | July 5, 2021 | |||||||
A SBIR Phase II contract was awarded to Orphagen Pharmaceuticals in August, 2019 for $1,093,784.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44HD100256-01 | Phase II | 1,093,784 | August 12, 2019 | |||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals in July, 2015 for $224,954.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43CA200076-01 | Phase I | 224,954 | July 1, 2015 | |||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals in September, 2015 for $325,051.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43HL124897-01A1 | Phase I | 325,051 | September 1, 2015 | |||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $250,507.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43CA163009-01A1 | Phase I | 250,507 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $218,858.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DK071461-01 | Phase I | 218,858 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $499,746.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43CA099875-01A1 | Phase I | 499,746 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $144,158.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DK065426-01 | Phase I | 144,158 | ||||||||
A SBIR Phase II contract was awarded to Orphagen Pharmaceuticals for $961,179.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44MH075461-03 | Phase II | 961,179 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $446,635.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43TR000976-01A1 | Phase I | 446,635 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $520,358.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43CA150540-01 | Phase I | 520,358 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $220,839.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43HD068078-01A1 | Phase I | 220,839 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $223,229.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DK102221-01A1 | Phase I | 223,229 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $266,559.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43DK079452-01A1 | Phase I | 266,559 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $303,596.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43NS059219-01 | Phase I | 303,596 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $258,166.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AR055427-01 | Phase I | 258,166 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $270,181.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI060447-01 | Phase I | 270,181 | ||||||||
A SBIR Phase I contract was awarded to Orphagen Pharmaceuticals for $460,339.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43MH075461-01 | Phase I | 460,339 |